Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial (SUSHI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03318783|
Recruitment Status : Active, not recruiting
First Posted : October 24, 2017
Last Update Posted : April 10, 2019
|Condition or disease||Intervention/treatment||Phase|
|Subarachnoid Hemorrhage, Aneurysmal Delayed Cerebral Ischemia Vasospasm, Cerebral Endothelial Dysfunction||Drug: GSK2256294 Drug: Placebo||Phase 1 Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Subjects will be randomized to one of the two treatment arms based on an unrestricted or "fair-coin" randomization procedure.|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Investigational pharmacy staff will maintain the randomization list and study/drug placebo assignment. Participants, care providers, the investigators and outcomes assessors will be blinded to the grouping.|
|Official Title:||Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial|
|Actual Study Start Date :||May 2, 2018|
|Estimated Primary Completion Date :||June 2021|
|Estimated Study Completion Date :||December 2021|
Active Comparator: GSK2256294
10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.
GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
Placebo Comparator: Placebo
10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.
Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
- Number of participants with treatment-related adverse events [ Time Frame: 90 days ]
Summary tables and listings will be provided for all reported adverse events, defined as adverse events that start on or after the first administration of study drug. The reported adverse event term will be assigned a standardized preferred term.
Adverse events will be summarized based on the number and percentage of patients experiencing the event. In the event a patient experiences repeat episodes of the same adverse event, then the event with the highest severity grade and strongest causal relationship to study treatment will be used for purposes of incidence tabulations. Tabular summaries will be provided for all adverse events, the relationship to study drug treatment the maximum severity grade, action taken, and whether the event qualified serious adverse event or not.
All deaths will be reported in a patient listing, which will include the primary cause of death and the number of days between the date of the last dose of study drug and death.
- Study day 7 and study day 10 serum and CSF EET/ dihyroxyeicosatrienoic (DHET) ratio, by mass spectroscopic analysis (ng/mL) [ Time Frame: 10 days ]
Day 7 and day 10 serum EET/DHET ratios will be measured by liquid chromatography and mass spectroscopy of collected blood samples.
Day 7 and day 10 CSF EET/DHET ratios will be measured by liquid chromatography and mass spectroscopy of collected CSF samples.
- Study day 7 and study day 10 serum epoxyoctadecenoic acid (EPOME) to dihydroxyoctadec-12-enoic acid (DPOME) ratio, by mass spectroscopic analysis (ng/mL) [ Time Frame: 10 days ]Study day 7 and study day 10 serum epoxyoctadecenoic acid (EPOME) to dihydroxyoctadec-12-enoic acid (DPOME) ratio, will be measure by mass spectroscopic analysis of collected blood samples.
- Serum biomarkers of endothelial injury from blood samples obtained on study day 7 and study day 10 [ Time Frame: 10 days ]The following serum biomarkers will be obtained from collected blood samples by Luminex assay: e-selectin (pg/mL), p-selectin (pg/mL), Vascular cell adhesion marker (VCAM-1) (pg/mL), Platelet endothelial cell adhesion marker (PECAM-1, CD31) (pg/mL), intercellular adhesion molecule (ICAM-1) (pg/mL)
- CSF biomarkers of neuroinflammation, from blood samples obtained on study day 7 and study day 10 [ Time Frame: 10 days ]The following CSF biomarker will be obtained from collected CSF samples by Luminex assay: Tumor necrosis factor alpha (TNF-α) (pg/mL), Interleukin 1β (IL-1β) (pg/mL), Interferon gamma (IFN-γ) (pg/mL), Interleukin 6 (IL-6) (pg/mL), Interleukin 8 (IL-8) (pg/mL), Monocyte chemoattractant protein 1 (MCP-1) (pg/mL)
- Hospital length of stay in days [ Time Frame: 90 days ]The hospital length of stay will be recorded in days, at the time of hospital discharge.
- Discharge disposition [ Time Frame: 90 days ]The disposition from the hospital in one of the following categories: home, home with services, rehab, long term acute care facility, skilled nursing facility, hospice, death
- Incidence of new stroke on hospital discharge imaging [ Time Frame: 90 days ]The last head CT or other brain imaging to detect the presence of a new area of cerebral infarction will be reviewed at the time of hospital discharge. A cerebral infarction will be defined as a one identified on hospital discharge that was not present on imaging between 24-48 hours after aneurysm occlusion, and not attributable to other causes such as surgical clipping or endovascular treatment. Hypodensities resulting from extraventricular drains or residual intraparencyhmal hematomas will not be considered new strokes.
- Modified Rankin scale (mRS) at hospital discharge and 90 day follow up [ Time Frame: 90 days ]The mRS score will be determined by patient or surrogate interview, at both hospital discharge and 90 day follow up. Scores will be assigned based on the following: 0 - no symptoms, 1 - no significant disability, able to carry out all usual activities despite some symptoms, 2 - slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 - moderate disability, requires some help, but able to walk unassisted, 4 - moderately severe disability, unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 - severe disability, requires constant nursing care and attention, bedridden, incontinent, 6 - deceased.
- Extended Glasgow Outcome Scale (GOSE) Score at 90 day follow up [ Time Frame: 90 days ]At 90 day follow up, the GOSE will be determined by patient or surrogate telephone interview, based on a structured interview of 19 questions. The GOSE will be recorded on an a scale of 1-8 where 1 - deceased, 2 - vegetative state, 3 - low severe disability, 4 - upper severe disability, 5 - low moderate disability, 6 -upper moderate disability, 7 - low good recovery, 8 - upper good recovery.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03318783
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 97239|
|Principal Investigator:||Ross Martini, MD||Oregon Health and Science University|